safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-18Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESОсобенности распределения фуллереновых наночастиц в организме при проведении доклинических исследованийThe distribution of fullerene n anoparticles in the body in preclinical studiesАляутдинРенад НиколаевичAlyautdinR. N.Alyautdin@expmed.ruРомановБорис КонстантиновичRomanovB. K.noemail@neicon.ruМеркуловВадим АнатольевичMerkulovV. A.noemail@neicon.ruФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииRussian Federation201520022018032229Copyright © Аляутдин Р.Н., Романов Б.К., Меркулов В.А., 20182018Аляутдин Р.Н., Романов Б.К., Меркулов В.А.Alyautdin R.N., Romanov B.K., Merkulov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/18

C60 фуллерен, состоящий из 60 атомов углерода, представляет собой замкнутую структуру, включающую 12 пентагональных и 20 гексагональных граней. Диаметр молекулы составляет 0,71 нм. Фуллерены являются третьим, после графита и алмаза, состоянием углерода. Фуллереновые наночастицы плохо всасываются из ЖКТ, и это затрудняет исследование закономерностей их распределения в организме. Однако, при системном введении анализ распределения фуллеренов указывает на типичное для наночастиц с немодифицированной поверхностью распределение по органам: накопление в органах, содержащих клетки ретикуло-эндотелиальной системы: печени, селезенке и легких. Специфической особенностью фуллеренов является их медленное выведение из организма, что в первую очередь обусловлено практически отсутствием метаболизма этих структур в организме.

C60 fullerene consisting of 60 carbon atoms is a closed structure comprising 12 hexagonal and 20 pentagonal faces. The diameter of the molecule is 0.71 nm. Fullerenes are the third,after graphite and diamond carbon state. Fullerene nanoparticles are poorly absorbed from the gastrointestinal tract,therefor it is difficult to study the pattern of their distribution in the body. However,when fullerenes are administered systemically their distribution is typical for distribution of nanoparticles with the non-modified surface - the accumulation in organs containing cells of the reticuloendothelial system: the liver,spleen and lungs. A specific feature of fullerenes is their slow elimination from the body, which is primarily due to very slow metabolism of these structures.

нанотехнологиифуллереныРЭСпеченьтоксичностьnanotechnologyfullereneRESlivertoxicityReferencesKroto H.W., Heath J.R., O’Brien S.C., Curl R.F., Smalley R.E. C60: buckminsterfullerene. Nature 1985; 318:162-3Kroto HW, Heath JR, O’Brien SC, Curl RF, Smalley RE. C60: buckminsterfullerene. Nature 1985; 318:162–3Piskoti C., Yarger J., Zettl A. (1998) C36, a new carbon solid. Nature 1998; 393:771-4.Piskoti C, Yarger J, Zettl A (1998) C36, a new carbon solid. Nature 1998; 393:771–4.Torres V.M., Posa M., Srdjenovic B., Simpli'cio A.L. Solubilization of fullerene C60 in micellar solutions of different solubilizers. Colloids Surf B Biointerfaces 2011; 82:46-53.Torres VM, Posa M, Srdjenovic B, Simplı´cio AL. Solubilization of fullerene C60 in micellar solutions of different solubilizers. Colloids Surf B Biointerfaces 2011; 82:46–53.Deguchi S., Alargova R.G., Tsujii K. Stable dispersions of fullerenes, C-60 and C-70, in water. Preparation and characterization. Langmuir 2001; 17:6013-17.Deguchi S, Alargova RG, Tsujii K . Stable dispersions of fullerenes, C-60 and C-70, in water. Preparation and characterization. Langmuir 2001; 17:6013–17.Makha M., Purich A., Raston C.L. et al. Structural diversity of host-guest and intercalationcomplexes of fullerene C 60. Eur J InorgChem 2006; 37:507-15.Makha M, Purich A, Raston CL et al. Structural diversity of host-guest and intercalationcomplexes of fullerene C 60 . Eur J InorgChem 2006; 37:507–15.Husebo L.O., Sitharaman B., Furukawa T. et al. Fullerenols revisited as stable radical anions. J Am Chem Soc. 2004 126:12055-64.Husebo LO, Sitharaman B, Furukawa T et al. Fullerenols revisited as stable radical anions. J Am Chem Soc. 2004 126:12055–64.Da Ros T., Prato M. Medicinal chemistry with fullerenes and fullerene derivatives. Chem Comm 1999; 8:663-9.Da Ros T, Prato M. Medicin al chemistry with fullerenes and fullerene derivatives. Chem Comm 1999; 8:663–9.Bensasson R.V., Berberan-Santos M.N., Brettreich et al. Triplet state properties of malonic acid C60 derivatives C60[C(C00R)2]n; R = H, Et; n = 1-6. Phys Chem Chem Phys 2001; 3:4679-4683.Bensasson RV, Berberan-Santos MN, Brettreich et al. Tri plet state properties of malonic acid C60 derivatives C60[C(COOR)2]n; R = H, Et; n = 1–6. Phys Chem Chem Phys 2001; 3:4679–4683.Markovic Z., Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 2008; 29:3561-73.Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 2008; 29:3561–73.Руководство по проведению доклинических исследований лекарственных средств. Под редакцией А.Н. Миронова. М.: Гриф и К. 2012.Руководство по проведению доклинических исследований лекарственных средств. Под редакцией А.Н. Миронова. М.: Гриф и К. 2012.Yamago S., Tokuyama H., Nakamura E., Kikuchi K. et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem Biol 1995; 2:385-389.Yamago S, Tokuyama H, Nakamura E, Kikuchi K et al. In vivo biological behavior of a watermiscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem Biol 1995; 2:385–389.Mori T., Takada H., Ito S., Matsubayashi K., Miwa N., Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 2006; 225:48-54.Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 2006; 225:48–54.Chen H.H., Yu C., Ueng T.H., Chen S., Chen B.J. Acute and subacute toxicity study of water soluble polyalkylsulfonated C60 in rats. Toxicol Pathol 1998; 26:143-151.Chen HH, Yu C, Ueng TH, Chen S, Chen BJ. Acute and subacute toxicity study of water soluble polyalkylsulfon ated C60 in rats. Toxicol Pathol 1998; 26:143–151.Yamashita K., Yoshioka Y., Pan H. Biochemical and hematologic effects of polyvinylpyrrolidone-wrapped fullerene C60 after oral administration. Pharmazie 2013; 68(1):54-7.Yamashita K, Yoshioka Y, Pan H. Biochemical and hematologic effects of polyvinylpyrrolidonewrapped fullerene C60 after oral administration. Pharmazie 2013; 68(1):54-7.Folkmann J.K., Risom L., Jacobsen N.R., Wallin H. Oxidatively damaged DNA in rats exposed by oral gavage to C60 fullerenes and single-walled carbon nanotubes. Environ Health Perspec 2009; 117:703-708.Folkmann JK, Risom L, Jacobsen NR, Wallin H. Oxidatively damaged DNA in rats exposed by oral gavage to C60 fullerenes and single-walled carbon n anotubes. Environ Health Perspec 2009; 117:703–708.Gharbi N., Pressac M., Hadchouel M. (2005) [60] Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 2005; 5:2578-85.Gharbi N, Pressac M, Hadchouel M. (2005) [60] Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 2005; 5:2578–85.Zogovic N.S., Nikolic N.S., Vranjes-Djuric S.D. et al. Opposite effects on nanocrystalline fullerene (C60) on tumor cell growth in vitro and in vivo and a possible role of immunosuppression in the cancerpromoting activity of C60. Biomaterials 2009; 30:6940-6946.Zogovic NS, Nikolic NS, Vranjes-Djuric SD et al. Opposite effects on n anocrystalline fullerene (C60) on tumor cell growth in vitro and in vivo and a possible role of immunosuppression in the cancerpromoting activity of C60. Biomaterials 2009; 30:6940–6946.Chien C.T., Lee P.H., Chen C.F., Ma M.C. De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J Am Soc Nephrol 2001; 12:973-982Chien CT, Lee PH, Chen CF, Ma MC. De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J Am Soc Nephrol 2001; 12:973–982Ueng T.H., Kang J.J., Wang H.W. Suppression of microsomal cytochrome P450-dependent monooxygenases and mitochondrial oxidative phosphorylation by fullerenol, a polyhydroxylated fullerene C60. Toxicol Lett 1997; 93:29-37Ueng TH, Kang JJ, Wang HW. Suppression of microsomal cytochrome P450-dependent monooxygen ases and mitochondrial oxidative phosphorylation by fullerenol, a polyhydroxylated fullerene C60. Toxicol Lett 1997; 93:29–37Milic V.D., Stankov K., Injac R., Djordjevic A. et al. Activity of antioxidative enzymes in erythrocytes after a single dose administration of doxorubicin in rats pretreated with fullerenol C60(0H)24. Toxicol Mech Methods 2009; 19:24-28.Milic VD, Stankov K, Injac R, Djordjevic A et al. Activity of antioxidative enzymes in erythrocytes after a single dose administration of doxorubicin in rats pretreated with fullerenol C60(OH)24. Toxicol Mech Methods 2009;19:24–8.Injac R., Perse M., Cerne M., Potocnik N. et al. Protective effects of fullerenol C60(0H)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009; 30:1184-1196.Injac R, Perse M, Cerne M, Potocnik N et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009; 30:1184–1196.Sumner S.C., Snyder R.W., Wingard C. Distribution and biomarkers of carbon-14-labeled fullerene C60 ([14 C(U)]C60 ) in female rats and mice for up to 30 days after intravenous exposure. J Appl Toxicol 2015. Doi: 10.1002/jat.3110.Sumner SC, Snyder RW, Wingard C. Distribution and biomarkers of carbon-14-labeled fullerene C60 ([14 C(U)]C60 ) in female rats and mice for up to 30 days after intravenous exposure. J Appl Toxicol 2015. Doi: 10.1002/jat.3110.Snyder R.W., Fennell T.R., Wingard C.J. Distribution and biomarker of carbon-14 labeled fullerene C60 ([14 C(U)]C60 ) in pregnant and lactating rats and their offspring after maternal intravenous exposure. J Appl Toxicol 2015 doi: 10.1002/jat.3177.Snyder RW, Fennell TR, Wingard CJ. Distribution and biomarker of carbon-14 labeled fullerene C60 ([14 C(U)]C60 ) in pregn ant and lactating rats and their offspring after matern al intravenous exposure. J Appl Toxicol 2015 doi: 10.1002/jat.3177.Nikolicr N., Vranjes-Ethuricr S., Jankovicr. Preparation and biodistribution of radiolabeled fullerene C60 nanocrystals. Nanotechnology 2009; 20:385102.Nikolic´ N, Vranjes-Ethuric´ S, Jankovic´. Preparation and biodistribution of radiolabeled fullerene C60 n anocrystals. Nanotechnology 2009; 20:385102.Li Z., Pan L.L., Zhang F.L. Preparation and characterization of fullerene (C60) amino acid nanoparticles for liver cancer cell treatment. J Nanosci Nanotechnol 2014 Jun;14(6):4513-8.Li Z, Pan LL, Zhang FL. Preparation and characterization of fullerene (C60) amino acid n anoparticles for liver cancer cell treatment. J Nanosci Nanotechnol 2014 Jun;14(6):4513-8.Shamenkov D.A., Petrov V.E., Alyautdin R.N. Effects of apolipoproteins on dalargin transport across the blood-brain barrier. Bulletin of Experimental Biology and Medicine 2006; 142: 703-706.Shamenkov D.A., Petrov V.E., Alyautdin R.N. Effects of apoli poproteins on dalargin transport across the blood-brain barrier. Bulletin of Experimental Biology and Medicine 2006; 142: 703-706.Аляутдин Р.Н., Романов Б.К., Лепахин В.К. и соавт. Связанный с альбуминовыми наночастицами паклитаксел - первые шаги нанотехнологий в клиническую практику. Безопасность и риск фармакотерапии 2014; 2: 10-17.Alyautdin R, Romanov B., Lepakhin V. et al. Coupled to albumin paclitaxel – the first step of n anotechnologies into clinical practice. Safety and risk of pharmacotherapy 2014. 2. 10-17

The authors declare that there are no conflicts of interest present.